Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro…
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical…
Phase 2 CADENCE Trial Shows Positive Results, Establishing WINREVAIR™ as a Proof-of-Concept Therapy in CpcPH and HFpEF Merck & Co.—known as MSD outside the United States and Canada—has unveiled comprehensive…
Bepirovirsen advances to regulatory review by the European Medicines Agency as a promising first-in-class therapy for chronic hepatitis B GSK plc has announced a significant regulatory milestone as the European…
Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on…
AbbVie to Present New Clinical and Real-World Evidence Advancing Care Standards in Immune-Mediated Skin Diseases at the AAD Annual Meeting 2026 AbbVie has announced a comprehensive slate of new research…
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data…
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems, widely recognized as a leading provider of post-acute care…
Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology Sensus Healthcare, Inc., a developer of non-invasive and minimally invasive technologies for the treatment of both oncological and non-oncological skin…
LEO Pharma Presents New Long-Term Data for SPEVIGO® (spesolimab-sbzo) in Adults with Generalized Pustular Psoriasis at AAD 2026 LEO Pharma A/S has announced new long-term clinical data supporting the use…
Banner|Aetna Engages Community at the 2026 Phoenix Heart Walk Banner|Aetna, an integrated health plan formed through a collaboration between Banner Health and CVS Health through its Aetna business, is actively…